New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.

Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond appetite suppression. If confirmed in humans, the finding could help explain the drug’s powerful benefits and inspire more comprehensive treatments for obesity and diabetes.

Saturday, September 26 – Chipotle, McDonald’s and Shake Shack are among the restaurant chains revamping their menus as more consumers go on weight-loss drugs.

Saturday, September 26 – Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a reported 5-year survival rate of approximately 13.3%, largely because of late diagnosis, rapid progression and resistance to treatment. GAIP-interacting protein C terminus 1 (GIPC1), overexpressed in PDAC, is a scaffolding protein that stabilizes multiple oncogenic receptors and signaling complexes involved in proliferation, survival, adhesion, migration and chemoresistance.

Friday, September 25 – Mylan Pharmaceuticals Inc. has launched a lawsuit in Delaware federal court asking for a finding that its proposed generic version of Novo Nordisk Inc.’s blockbuster weight loss drug Wegovy does not infringe a patent, the latest salvo in a larger intellectual property fight over the GLP-1.

Friday, September 25 – FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”

Friday, September 25 – People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a Florida State University professor.

Friday, September 25 – Children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk: nutritional deficiencies. A new study found that nearly 1 in 6 young patients developed a diagnosed deficiency within a year of starting treatment, with vitamin D deficiency affecting about 12%.

Thursday, September 24 – Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal suggests that this effect cannot be entirely explained by patients losing weight on the drug.

Thursday, September 24 – (MedPage Today) — The FDA issued a warning letter this month to Empower Pharmacy over its mass production of compounded GLP-1 weight-loss and diabetes drugs, citing illegal copycat manufacturing and insanitary conditions.
Following a facility…

Thursday, September 24 – Woman who used semaglutide and lost vision is among people suing the makers of GLP-1 weight-loss drugs for not being warned about potential vision loss.

Wednesday, September 23 – Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more than 30% on Tuesday.

Wednesday, September 23 – With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.

Wednesday, September 23 – With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obesity.

Wednesday, September 23 – (MedPage Today) — Note that some links may require registration or subscription.
Dozens of Americans sued manufacturers of GLP-1 receptor agonists, claiming the drugmakers failed to warn patients about the risk of non-arteritic anterior ischemic…

Wednesday, September 23 – The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmot Therapeutics as well as partner Zealand Pharma.

Wednesday, September 23 – Heidi Skolnik, a sports nutritionist, exercise physiologist and bestselling author, joins TODAY to discuss her latest book, “Your GLP-1 Game Plan,” that is filled with guidance on what to eat and how to move and thrive on weight loss medications. “The medication doesn’t give you nourishment, and it doesn’t give you strength. You really need to go beyond the scale to think about your ‘why.’ And we know that when you focus on health beyond appearance, you do better,” she says.

Wednesday, September 22 – About 11% of Americans are taking a GLP-1 medication, up considerably from 3% in 2024, according to a recent Gallup poll.

Tuesday. September 22 – Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned of the potential danger of vision loss. In statements, Novo Nordisk says, in part, they are “vigorously” fighting the lawsuits, saying they are “without merit,” while Eli Lilly says in part, it maintains “patient safety” is its “top priority.” NBC News’ Stephanie Gosk has the story.

Tuesday. September 22 – Children prescribed GLP-1 medications for weight loss, prediabetes or type 2 diabetes are at risk for nutritional deficiencies—diagnosed in nearly one in six patients (16.8%) within the first year—according to a new study published in the journal Childhood Obesity. Vitamin D deficiency was the most common, identified in 12.4% of children within one year of GLP-1 treatment.

Tuesday, September 22 – GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight—primarily as fat.

Tuesday, September 22 – A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.

Saturday, September 19 – Research shows that microdosing GLP-1 medications may still lead to weight loss. Tatsiana Volkava · Moment/Getty

Recent research suggests that people may still lose weight while staying on the lowest starting doses of GLP-1 medications, such as Wegovy or Zepbound, for longer periods.

After one year, people taking sustained low dose tirzepatide lost about 5.5% of their body weight, while those taking sustained low dose semaglutide lost about 2.2%.

Lower doses were associated with more modest weight loss than higher doses, but sustained low dose semaglutide was also associated with lower rates of some side effects.

Saturday, September 19 – (MedPage Today) — Frailty did not appear to prevent adults with cardiovascular disease and overweight or obesity from reaping the benefits of semaglutide (Wegovy), a secondary analysis of SELECT trial data indicated.
By week 104, semaglutide…

Saturday, September 19 – Ozempic and other GLP-1 medications can improve blood sugar, weight, and cardiovascular health, but researchers found little evidence that they also improve mental health, employment, marriage, or overall well-being. The findings suggest the drugs’ broader life effects may be subtler than their dramatic physical health benefits.

Friday, September 18 – Millions of people worldwide—as many as 1 in 8 adults in the U.S.—are taking GLP-1 medications, such as Ozempic, Mounjaro, Wegovy and Zepbound, to treat diabetes or for weight loss.

Thursday, September 17 – Retatrutide, an experimental weight loss drug still undergoing clinical trials at Eli Lily, is being marketed online and illegally sold to U.S. clients, a CBS News investigation found. CBS News investigative reporter and producer Daniel Gilbert has the story.

An Illinois federal judge is weighing whether the state’s genetic privacy law protects against disclosing information about people who have taken genetic tests, with a DNA testing company accused of unlawfully sharing such information with Google arguing Wednesday the statute applies only to disclosure of actual test results.

Thursday, September 17 – Elvinix Inc. has announced an exclusive license agreement with Zealand Pharma A/S granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio.

Wednesday, September 16 – (MedPage Today) — An international consensus panel outlined the first clinical framework for implementing general-population screening for islet autoantibodies to catch early-stage type 1 diabetes. (Diabetologia)
Another international consensus…

Tuesday, September 15 – (MedPage Today) — Blockbuster GLP-1 receptor agonists revolutionized obesity management in recent years, driving weight loss of up to 20%.
This weight loss, however, can carry a notable downside: Studies estimate that 15% to 40% of GLP-1-induced…

Tuesday, September 15 – The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.

Monday, September 14 – A study linked 15 cases of Wernicke encephalopathy to GLP-1 drugs like Ozempic and Mounjaro, raising concerns about vitamin B1 deficiency risks.

AI analysis of 400,000 Reddit posts found that users of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reported unexpected symptoms including menstrual changes, chills, hot flashes, and fatigue. Researchers cannot say the medications caused these problems, but the patterns may reveal overlooked signals worth studying.

GLP-1 drugs such as Ozempic, Wegovy, and Zepbound may increase hair-loss risk by 7% in men who are already genetically susceptible to male-pattern baldness. The findings suggest thinning hair may not be caused only by rapid weight loss and could also reflect a biological link between GLP-1 activity and hair follicles.

Sunday, September 13 – Semaglutide helped older healthy mice live longer while improving memory, muscle function, blood sugar control, and several biological signs of aging. Its effects went beyond those seen with calorie restriction, raising the possibility that GLP-1 drugs could tap into a separate biological pathway linked to longevity.

Saturday, September 12 – Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or falseFALSE “GLP-1 medications mimic Glucagon-like peptide-1 – one of the hormones involved in appetite regulation. It doesn’t completely suppress hunger, but it is powerful,” says Dr Federica Amati, nutrition lead at Imperial College School of Medicine and author of The Appetite Reset. “The medicine is about 1,000 times stronger than what we naturally produce from our gut,” she explains. As food passes through the gut, cells called L-cells sense the nutrients, which sparks the production of the GLP-1 hormone.

Friday, September 11 – As weight loss drugs have risen all around the world, it has reshaped users’ relationships for better and for worseAs GLP-1 use continues to rise in the US and the UK, people’s bodies are being reshaped – as are their relationships.“Relationships tend to develop a sense of equilibrium and predictability over time,” says Dr Lindsey Berisha, a licensed clinical psychologist who has worked with clients using GLP-1s for over 10 years. “When one partner undergoes a significant change, it can shift that equilibrium, and even positive change can create uncertainty for both partners.” Continue reading…

Thursday, September 10 – Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.

Thursday, September 10 – Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers say GLP-1 drugs may offer respiratory benefits in addition to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.